Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
105 participants
INTERVENTIONAL
2023-03-15
2023-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The standard treatment of symptomatic leiomyomas is Abdominal myomectomy Blood loss during myomectomy can be intra-operative or postoperative and with hematoma formation. The average volume of blood loss during abdominal myomectomy is 200 to 800 ml. massive blood loss associated with the dissection of huge fibroids renders myomectomy a more technically challenging procedure than hysterectomy. Sometimes myomectomy is converted to hysterectomy intra-operatively when bleeding becomes heavy and uncontrollable or when it is impossible to reconstruct the uterus because of the many defects left by removal of multiple myomas .
Many techniques are used to reduce blood loss during myomectomy; preoperative measures such as correction of preoperative anemia associated with menorrhagia may be treated with iron supplementation, use of gonadotropin (GHG) triggers prior to surgery. Intra-operative measures as use of tourniquet around the uterus during the operation, injections of Vasopressin or other vasopressors as epinephrine in the uterine muscle and use of ecbolic (misoprostol, oxytocin, and carbetocin etc.). Uterine artery ligation, embolization, or internal iliac artery ligation may also be used to avoid hysterectomy when heavy bleeding is anticipated or occurs during myomectomy
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Misoprostol Versus Oxytocin Infusion On Reducing Blood Loss During Abdominal Myomectomy
NCT06325501
Safety of Tranexamic Acid in Reducing Blood Loss Myomectomy.
NCT04694677
Intravenous Oxytocin Versus Tranexamic Acid in Reducing Blood Loss During Abdominal Myomectomy.
NCT03892668
Reducing Operative Blood Loss in Laparoscopic Myomectomy With Umbilico-uterine Trunk Clipping
NCT07200778
Vaginal Misoprostol Versus Bilateral Uterine Artery Ligation in Decreasing Blood Loss in Trans-abdominal Myomectomy
NCT02643186
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aim of the study is to compare the effectiveness of a single preoperative dose of rectal misoprostol, intramyometrial oxytocin, intramyometrial carbetocin, combined iv TXA acid and ethamsylate and peri cervical tourniquet for the reduction of blood loss during of abdominal myomectomy.
Methodology:
Type of Study: Prospective randomized comparative clinical trial Study Setting: This study will be conducted in Cairo University, kasr al-ainy hospitals, Maternity hospital in operative theater.
Study Period: 6 months from April 2023 to October 2023. Study Population: Patients will be recruited in this study from those attending gynecology ward at Kasr al-ainy hospitals, Maternity hospital who are 25-48 years old with symptomatic uterine myoma indicating operative management, abnormal uterine bleeding or bulk-related symptoms, females with infertility or recurrent pregnancy loss, pressure symptoms, and large myoma(s).
Basic assessment:
* Verbal consent was obtained before history taking All women were subjected to
* Detailed clinical history.
* Personal history:
Name, Age, Parity, Occupation, Residency and Special habits.
· Present history: History of onset, course and duration of agonizing symptoms, history of HMB, history of infertility, history of pelvic pain.
• Obstetric history: History of previous abortion, ectopic pregnancy, previous cesarean section and interval between cesarean deliveries.
· Menstrual history: Age of menarche and LMP.
· Past history: History of medical disorders, drug therapy or allergy, history of appendicitis - in particular, appendix rupture, history of exposure to radiation treatment for cancer, history of Gynecological infections (PID), history of abdominal infections e.g.: peritonitis, history of any abdominal or pelvic operation for non-obstetric cause.
• Family history: Family history of uterine myoma, family history of uterine cancers. Examination
* General examination includes blood pressure, heart rate, body temperature, head\& neck examination, chest, heart, sign of anemia, height (in cm) and weight (in kg) measurements to calculate the Body mass index (The formula for BMI is weight in kilograms divided by height in meters squared).
* Local clinical examination: assessment of maternal health, abdominal and bimanual examination, speculum examination to roll out any vaginal or cervical infection and local cause of bleeding.
* Preoperative investigations (Complete blood picture, blood group, RH, Kidney Function Test , Liver Function Test , random Blood Sugar , urine analysis, Coagulation profile).
* Ultrasonography examination (abdominal / vaginal) and MRI: to assess the following data:
Presence of uterine myoma, size and site of myoma, uterine size, roll out any adnexal mass.
Intervention
All women will be randomly assigned to either:
Group A (misoprostol) (25 patient): who will receive 800 microgram (tablet 200mcg X 4) misoprostol (Misotac 200 mcg, SIGMA pharmaceutical, Egypt) rectally one and half hour before operation.
Group B (Tourniquet) (25 patient): The operation will be performed with the use of Foleys catheter as an improvised tourniquet applied at the base of the uterus close to the insertion of the uterosacral ligaments a minor hole through the broad ligament on either side of the uterus will be made, the catheter will be passed through the two holes and knotted firmly anteriorly around the uterus, the tourniquet will be tensed in stepwise manner by alternatively holding with a clamp, pulling on the tourniquet, and again holding with another clamp in such a way that it temporarily impedes the blood supply from the uterine vessels. The fallopian tubes, the ovaries, and the infundibulopelvic ligament are kept away to avoid compression by tourniquet then operation will be performed after infiltration of the serosa and / or myometrium overlying the leiomyoma before uterine incision with a solution composed of 50 ml Bupivacaine Hcl 0.25% (Bucain® Weimer pharma, for Actavis Group PTC) and 0.5 mg of epinephrine Hcl (2 vials of Epinephrine® 0.25mg/1ml Misr Co. for Pharmaceutical Industries). The solution will be prepared just before the procedure. Before each infiltration, aspiration will be performed to avoid intravascular injection.
Group C (Carbetocin) (25 patients): intramural; preparation of 100 μg of carbetocin ((Pabal, Ampoule 100 mcg in 1 ml, Carbetocin; FERRING, North York, Canada) diluted within 10 cm of saline (0.9%) in sterile syringe then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.
Group D (Oxytocin) (25 patients): who will receive oxytocin 40 I.U. intramyometrially (Syntocinon, Ampule 10 I.U. in 1 ml, Oxytocin; NOVARTIS, Basel, Switzerland) then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.
Group E (combined TXA and ethamsylate) (Patient 25): will receive 1 g tranexamic acid (2 ampoules of kapron 500 mg, kapron®, Amoun, Egypt) and 500 mg ethamsylate (2 ampoule of ethamsylate 250 mg, Dicynone, OM pharma, Geneva, Switzerland) IV 10 minutes before skin incision by slowly intravenous injection Then infusion was applied continuously for 24 hours within 1 liter of saline as 1 mg/kg/hour.
The operations will be performed by the same team to avoid any bias related to surgical skills. The abdomen will be exposed through Pfannenstiel incision, after skin incision, the subcutaneous fat and abdominal fascia will be opened crosswise, and the rectus muscle will be opened on the midline. The parietal peritoneum will be opened longitudinally to reach the pelvic cavity. Subsequently, a self-retaining retractor will be inserted, and intestine will be packed. Uterus will be inspected for the number, location, and shape of myomas, and other pelvic organs will be inspected for associated pathology. Uterine incisions on top of myoma will be performed. When possible, uterine incisions will be performed on the anterior wall or the fundus in order to reduce postoperative adhesions. The incision will be performed using monopolar diathermy. Intracapsular enucleation of myomas will be performed by gently dissecting between the myoma and the pseudo capsule. The myoma will be grasped by Collins forceps and gently enucleated out. Meticulous hemostasis will be secured by low-voltage coagulation (≤30 W) of feeding vessels. Myoma bed will be closed by 1 or 2 layers (The uterine defects will be closed with sutures in layers. If the myometrial defect is deep (\>2 cm), two layers may be needed to approximate the tissue and achieve hemostasis) of interrupted vicryl sutures (Vicryl 1-0 polyglactin 910; Egycryl, Taisier CO, Egypt). The serosa is closed with a running suture; we used size 2-0 polyglactin 910 (Vicryl). At the end of the surgery, 1 intraperitoneal suction drain will be routinely used and the volume in the drain bag will be measured every 12 hours. (Ultramed, Nelaton drain-24 FG, Assiut City, Egypt). in all patients the drains will be removed on the second postoperative day unless otherwise indicated. Number and size of myomas will be recorded. Myoma size represent the mean size of each myoma. Enucleated myomas will be sent to histopathology.
Total bleeding was calculated as intraoperative and postoperative blood loss. Intraoperative blood loss was estimated by the scrub nurse by drying up all blood in the surgical field with swabs and then weighing them. The weight of the dry surgical swabs (roughly 28 g for each 30 \* 30 cm abdominal swabs) is measured before use and after being wet or soaked by blood. A highly accurate digital balance is used to measure the weight in grams. The weight difference is translated into the blood loss considering that 1 g is equal to 1 mL blood. The quantity of blood loss (mL) equals (weight of the used materials - weight of the materials prior to the surgery) in addition to the blood collected in the suction apparatus after evacuation. Meanwhile, postoperative blood loss was defined as the blood volume found in the suction drain.
All study groups will be checked for vital signs (blood pressure, heart rate, and respiratory rate) before and after myomectomy. The following routine investigations, CBC, PT, PTT, ALT, AST and serum creatinine, will be performed preoperatively for all groups, and CBC will be repeated on the third postoperative day. Any adverse effects in either group will be recorded. The need for blood transfusion either intraoperatively or postoperatively will be also recorded. Intraoperative blood transfusion will be governed by clinical condition and amount of blood loss. Postoperative blood transfusion will be indicated if hemoglobin (Hb) percentage was less than 7 g/dl with relevant clinical manifestations. Women will be reviewed again 1 week after the operation. In addition to the usual follow-up, women will be checked for manifestations of thrombosis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
All women will be randomly assigned to either:
Group A (misoprostol): who will receive 800 microgram misoprostol rectally one and half hour before operation.
Group B (Tourniquet): The operation will be performed with the use of Foleys catheter as an improvised tourniquet applied at the base of the uterus.
Group C (Carbetocin): intramural; preparation of 100 μg of carbetocin diluted within 10 cm of saline (0.9%) Group D (Oxytocin): who will receive oxytocin 40 I.U. intramyometrially Group E (combined TXA and ethamsylate): will receive 1 g tranexamic acid and 500 mg ethamsylate IV 10 minutes before skin incision Group F receive terlipressin intramyometrial injection of one ampoule of vasopressin containing 20 units in1 ml after dilution in 19 ml of normal saline.
Group G: infiltration of the serosa and / or myometrium with a solution composed of 50 ml Bupivacaine 0.25% and 0.5 mg of epinephrine
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
misoprostol
15 patients will receive 800 microgram (tablet 200mcg X 4) misoprostol (Misotac 200 mcg, SIGMA pharmaceutical, Egypt) rectally one and half hour before operation.
Misoprostol
(15 patient): who will receive 800 microgram (tablet 200mcg X 4) misoprostol (Misotac 200 mcg, SIGMA pharmaceutical, Egypt) rectally one and half hour before operation.
Tourniquet
(15 patient): The operation will be performed with the use of Foleys catheter as an improvised tourniquet applied at the base of the uterus then infiltration myometrium overlying the leiomyoma with a solution composed of Bupivacaine Hcl 0.25% and 0.5 mg of epinephrine
Tourniquet
(15 patient): The operation will be performed with the use of Foleys catheter as an improvised tourniquet applied at the base of the uterus then infiltration myometrium overlying the leiomyoma with a solution composed of Bupivacaine Hcl 0.25% and 0.5 mg of epinephrine
Carbetocin
intramural; preparation of 100 μg of carbetocin ((Pabal, Ampoule 100 mcg in 1 ml, Carbetocin; FERRING, North York, Canada) diluted within 10 cm of saline (0.9%) in sterile syringe then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.
Carbetocin
(15 patients): intramural; preparation of 100 μg of carbetocin ((Pabal, Ampoule 100 mcg in 1 ml, Carbetocin; FERRING, North York, Canada) diluted within 10 cm of saline (0.9%) in sterile syringe then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.
Oxytocin
15 patients): who will receive oxytocin 40 I.U. intramyometrially (Syntocinon, Ampule 10 I.U. in 1 ml, Oxytocin; NOVARTIS, Basel, Switzerland) then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.
Oxytocin
(15 patients): who will receive oxytocin 40 I.U. intramyometrially (Syntocinon, Ampule 10 I.U. in 1 ml, Oxytocin; NOVARTIS, Basel, Switzerland) then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.
combined TXA and ethamsylate
(Patient 15): will receive 1 g tranexamic acid (2 ampoules of kapron 500 mg, kapron®, Amoun, Egypt) and 500 mg ethamsylate (2 ampoule of ethamsylate 250 mg, Dicynone, OM pharma, Geneva, Switzerland) IV 10 minutes before skin incision by slowly intravenous injection Then infusion was applied continuously for 24 hours within 1 liter of saline as 1 mg/kg/hour.
combined TXA and ethamsylate
(Patient 15): will receive 1 g tranexamic acid (2 ampoules of kapron 500 mg, kapron®, Amoun, Egypt) and 500 mg ethamsylate (2 ampoule of ethamsylate 250 mg, Dicynone, OM pharma, Geneva, Switzerland) IV 10 minutes before skin incision by slowly intravenous injection Then infusion was applied continuously for 24 hours within 1 liter of saline as 1 mg/kg/hour.
vasopressin
15 women will receive terlipressin (Glypressin, Ferring, Egypt) intramyometrial injection of one ampoule of vasopressin containing 20 units in1 ml after dilution in 19 ml of normal saline during myomectomy.
Vasopressin
15 patient intramyometrial injection of one ampoule of vasopressin containing 20 units in1 ml after dilution in 19 ml of normal saline during myomectomy.
bupivacaine and epinephrine
15 women in which the operation will be performed after infiltration of the serosa and / or myometrium overlying the leiomyoma before uterine incision with a solution composed of 50 ml Bupivacaine Hcl 0.25% (Bucain® Weimer pharma, for Actavis Group PTC) and 0.5 mg of epinephrine Hcl (2 vials of Epinephrine® 0.25mg/1ml Misr Co. for Pharmaceutical Industries).
Bupivacaine Hydrochloride 0.5 % Injectable Solution epinephrine
15 patient infiltration of the serosa and / or myometrium overlying the leiomyoma before uterine incision with a solution composed of 50 ml Bupivacaine Hcl 0.25% (Bucain® Weimer pharma, for Actavis Group PTC) and 0.5 mg of epinephrine Hcl (2 vials of Epinephrine® 0.25mg/1ml Misr Co. for Pharmaceutical Industries).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Misoprostol
(15 patient): who will receive 800 microgram (tablet 200mcg X 4) misoprostol (Misotac 200 mcg, SIGMA pharmaceutical, Egypt) rectally one and half hour before operation.
Tourniquet
(15 patient): The operation will be performed with the use of Foleys catheter as an improvised tourniquet applied at the base of the uterus then infiltration myometrium overlying the leiomyoma with a solution composed of Bupivacaine Hcl 0.25% and 0.5 mg of epinephrine
Carbetocin
(15 patients): intramural; preparation of 100 μg of carbetocin ((Pabal, Ampoule 100 mcg in 1 ml, Carbetocin; FERRING, North York, Canada) diluted within 10 cm of saline (0.9%) in sterile syringe then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.
Oxytocin
(15 patients): who will receive oxytocin 40 I.U. intramyometrially (Syntocinon, Ampule 10 I.U. in 1 ml, Oxytocin; NOVARTIS, Basel, Switzerland) then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.
combined TXA and ethamsylate
(Patient 15): will receive 1 g tranexamic acid (2 ampoules of kapron 500 mg, kapron®, Amoun, Egypt) and 500 mg ethamsylate (2 ampoule of ethamsylate 250 mg, Dicynone, OM pharma, Geneva, Switzerland) IV 10 minutes before skin incision by slowly intravenous injection Then infusion was applied continuously for 24 hours within 1 liter of saline as 1 mg/kg/hour.
Vasopressin
15 patient intramyometrial injection of one ampoule of vasopressin containing 20 units in1 ml after dilution in 19 ml of normal saline during myomectomy.
Bupivacaine Hydrochloride 0.5 % Injectable Solution epinephrine
15 patient infiltration of the serosa and / or myometrium overlying the leiomyoma before uterine incision with a solution composed of 50 ml Bupivacaine Hcl 0.25% (Bucain® Weimer pharma, for Actavis Group PTC) and 0.5 mg of epinephrine Hcl (2 vials of Epinephrine® 0.25mg/1ml Misr Co. for Pharmaceutical Industries).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. BMI less than 35 kg/m2
3. symptomatic uterine myomas..
4. myoma staging from (3 to 6) according to FIGO staging through trans vaginal ultrasonography (TVUSG) or magnetic resonance imaging (MRI) according to FIGO classification.
5. Maximum diameter of the largest myoma is 15 cm.
6. Uterine size between 14 to 28 weeks pregnancy.
Exclusion Criteria
2. Allergy to Misoprostol, carbetocin, TXA, ethamsylate, Oxytocin, vasopressin, bupivacaine and epinephrine.
3. Hypertension.
4. Cardiac and Pulmonary diseases.
5. Patients who have bleeding disorders.
6. Patients on antiplatelets or anticoagulant before surgery.
7. Anemia (Hb \< 10g %).
8. Chronic endocrine or metabolic diseases such as Diabetes.
9. Renal and hepatic impairment.
10. Obesity (body mass index \> 30 kg/m2).
11. Cases that will require intraoperative conversion of myomectomy to hysterectomy.
12. Intracavitary, submucosal, pedunculated Subserosal and adnexal Myoma FIGO staging 0,1,2,7,8.
13. history of Gynecological infections (PID), history of abdominal infections e.g.: peritonitis, history of any abdominal or pelvic operation for non-obstetric cause.
25 Years
48 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ahmed nagy shaker ramadan
lecturer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohammed A Taymour, MD
Role: PRINCIPAL_INVESTIGATOR
Cairo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
faculty of medicine, Kasr el ainy hospital, Cairo university
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Cooper JM, Brady RM. Intraoperative and early postoperative complications of operative hysteroscopy. Obstet Gynecol Clin North Am. 2000 Jun;27(2):347-66. doi: 10.1016/s0889-8545(00)80026-1.
Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update. 2016 Nov;22(6):665-686. doi: 10.1093/humupd/dmw023. Epub 2016 Jul 27.
Kongnyuy EJ, Wiysonge CS. Interventions to reduce haemorrhage during myomectomy for fibroids. Cochrane Database Syst Rev. 2014 Aug 15;2014(8):CD005355. doi: 10.1002/14651858.CD005355.pub5.
Krentel H, De Wilde RL. Complications in Laparoscopic Supracervical Hysterectomy(LASH), especially the morcellation related. Best Pract Res Clin Obstet Gynaecol. 2016 Aug;35:44-50. doi: 10.1016/j.bpobgyn.2015.11.001. Epub 2015 Nov 14.
Mohamed, S. E. S., Mansour, D. Y., & Shaker, A. N. (2019). The effect of misoprostol on intra-operative blood loss during myomectomy operation: Randomized controlled trial. Evidence Based Women's Health Journal, 9(1), 363-371.
Shady, N. W., Sallam, H. F., & Fahmy, H. (2018). Reducing blood loss during open myomectomy with intravenous versus topical tranexamic acid: A double-blinded randomized placebo-controlled trial. Middle East Fertility Society Journal, 23(3), 225-231.
Sirkeci RF, Belli AM, Manyonda IT. Treating symptomatic uterine fibroids with myomectomy: current practice and views of UK consultants. Gynecol Surg. 2017;14(1):11. doi: 10.1186/s10397-017-1014-4. Epub 2017 Jul 6.
Sleiman Z, Baba RE, Garzon S, Khazaka A. The Significant Risk Factors of Intra-Operative Hemorrhage during Laparoscopic Myomectomy: A Systematic Review. Gynecol Minim Invasive Ther. 2019 Nov 11;9(1):6-12. doi: 10.4103/GMIT.GMIT_21_19. eCollection 2020 Jan-Mar.
M Al-Morsi, A., N Abdul-Galeel, K., & A El-Desouky, E. S. (2021). Comparative study between oxytocin versus tranexamic acid and ethamsylate combination in reducing intraoperative blood loss in myomectomy. Al-Azhar Medical Journal, 50(3), 1893-1908.
Camanni M, Bonino L, Delpiano EM, Ferrero B, Migliaretti G, Deltetto F. Hysteroscopic management of large symptomatic submucous uterine myomas. J Minim Invasive Gynecol. 2010 Jan-Feb;17(1):59-65. doi: 10.1016/j.jmig.2009.10.013.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AN2023-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.